Epigen Biosciences enters a collaboration to license its LPA1 Receptor small molecule program to Novo Nordisk A/S for up to USD 200 Million

Epigen Biosciences enters a collaboration to license its LPA1 Receptor small molecule program to Novo Nordisk A/S for up to USD 200 Million

SAN DIEGO, May 23, 2018 /PRNewswire/ — Epigen Biosciences, Inc. announced today that it has entered into a collaboration agreement with Novo Nordisk A/S under which Novo Nordisk has licensed the LPA1 receptor antagonist EPGN696 for development in diabetic and chronic kidney